Literature DB >> 3680101

Growth of human-human hybridomas in serum-free media enhances antibody secretion.

M C Glassy1, R E Peters, A Mikhalev.   

Abstract

Human-human hybridomas derived from fusing lymph node lymphocytes with UC 729-6 were adapted to grow in commercially available serum-free medium and were compared with serum-supplemented [10% fetal bovine serum (FBS)] cultures. Over a 6-d period, no significant changes occurred in the growth of the cells in 10% FBS or serum-free medium. In cultures supplemented with 10% FBS more total proteins were secreted than in serum-free cultures. However, there was an enhanced secretion of three- to four-fold of both immunoreactive human IgG and IgM under serum-free conditions compared to serum-supplemented conditions. Serum-free conditions may provide the appropriate milieu for the increased level of Ig secretion from human hybridomas derived from UC 729-6 in that there are no inhibitors that may be present in serum.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680101     DOI: 10.1007/bf02623674

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  21 in total

1.  DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS.

Authors:  B J DAVIS
Journal:  Ann N Y Acad Sci       Date:  1964-12-28       Impact factor: 5.691

2.  Variations in the secretion of monoclonal antibodies by human-human hybridomas.

Authors:  S A Gaffar; C D Surh; M C Glassy
Journal:  Hybridoma       Date:  1986

3.  Use of mouse and human monoclonal antibodies in enzyme immunofiltration.

Authors:  M C Glassy; P H Cleveland
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

4.  Immunodetection of cell-bound antigens using both mouse and human monoclonal antibodies.

Authors:  M C Glassy; C D Surh
Journal:  J Immunol Methods       Date:  1985-07-16       Impact factor: 2.303

5.  Serum-free cell culture: a unifying approach.

Authors:  D Barnes; G Sato
Journal:  Cell       Date:  1980-12       Impact factor: 41.582

6.  UC 729-6, a human lymphoblastoid B-cell line useful for generating antibody-secreting human-human hybridomas.

Authors:  M C Glassy; H H Handley; H Hagiwara; I Royston
Journal:  Proc Natl Acad Sci U S A       Date:  1983-10       Impact factor: 11.205

7.  Development of a serum-free medium for growth of NS-1 mouse myeloma cells and its application to the isolation of NS-1 hybridomas.

Authors:  T Kawamoto; J D Sato; A Le; D B McClure; G H Sato
Journal:  Anal Biochem       Date:  1983-04-15       Impact factor: 3.365

8.  Determination of the optimal human cell lines for development of human hybridomas.

Authors:  P G Abrams; J A Knost; G Clarke; S Wilburn; R K Oldham; K A Foon
Journal:  J Immunol       Date:  1983-09       Impact factor: 5.422

9.  A human monoclonal antibody reactive with human prostate.

Authors:  D H Lowe; H H Handley; J Schmidt; I Royston; M C Glassy
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

10.  Immunization of dissociated spleen cell cultures from normal mice.

Authors:  R I Mishell; R W Dutton
Journal:  J Exp Med       Date:  1967-09-01       Impact factor: 14.307

View more
  4 in total

1.  Scale-up and optimization of culture conditions of a human heterohybridoma producing serotype-specific antibodies to Pseudomonas aeruginosa.

Authors:  U Schürch; S J Cryz; A B Lang
Journal:  Appl Microbiol Biotechnol       Date:  1992-07       Impact factor: 4.813

Review 2.  Physiological enhancement of immunoglobulin production of hybridomas in serum-free media.

Authors:  H Murakami; K Yamada; S Shirahata; A Enomoto; S Kaminogawa
Journal:  Cytotechnology       Date:  1991-01       Impact factor: 2.058

3.  Modified RPMI 1640 culture medium.

Authors:  G E Moore; D B Hood
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-04       Impact factor: 2.416

4.  Serum-free culture of AtT 20 pituitary cells: a system for neuroendocrine studies under defined conditions.

Authors:  H Vedder
Journal:  In Vitro Cell Dev Biol       Date:  1990-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.